UnknownNot Applicable

Proliferative Lupus Nephritis Treatment With Chloroquine and Hydroxychloroquine

Egypt60 participantsStarted 2018-09-18

Plain-language summary

Evaluation the efficacy of chloroquine and hydroxychloroquine in the treatment of proliferative lupus nephritis class III and IV in children and adolescents and evaluate the side effects of both drugs .

Who can participate

Age range10 Years – 18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Children and adolescents who fulfill diagnostics criteria of SLE and diagnosed with lupus nephritis class III and IV. * All patients will be received steroids , MMF and Angiotensin Converting Enzyme. Exclusion Criteria: * Patients diagnosed with lupus nephritis class I,II,V and VI. * Patients received Cyclophosphamide in stead of MMF.

What they're measuring

Fundus examination as screening test

Timeframe: 12 months

Trial details

NCT IDNCT03687905

SponsorTanta University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2019-03-31

Contact for this trial

Fatma S Gheet, M.B.,BCh

+201148157993 fatmagheet@gmail.com

View on ClinicalTrials.gov More Proliferative Nephritis trials